Cancer Archives

News and Trends 21 Mar 2016

CAR-T Startup Gets €51M from Top&New Investors

Autolus (UK) has secured over €51M in a recent series B round, led by the biggest Biotech VC in Europe – and a new player in life science investment. Autolus is a 1-year-old spin-off of the University College London (UCL) focusing on the development of next-generation CAR-T therapies, addressing current limitations of this ‘wonder therapy‘. […]

March 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

roche immuno oncology blueprint medicines boston

News and Trends 18 Mar 2016

Roche signs a €900M deal with an Immunotherapy Biotech in Boston

Roche (Switzerland) has picked 5 candidates from Blueprint Medicines (US) to complement its leading oncology pipeline. Roche is a leader in cancer therapies, but its position is threatened by intense competition, not to mention its stakes in the biosimilar war and some bad results from advanced trials. However, it seems that this Big Pharma still […]

March 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

gsk miltenyi biotech gmp cell gene therapy tcr car t

News and Trends 17 Mar 2016

GSK partners to Scale Manufacturing of CAR-T Therapies

Production of CAR-T therapies seems to be one of the biggest challenge of this promising technology. Miltenyi Biotec (Germany) and GSK have entered a new partnership to combine the clinical development of cell and gene therapies with manufacturing expertise. Milteniy is a German company of 1600 employees developing products for biomedical research and cellular therapy. It’s not the first […]

March 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

cellectis ucart leukemia cancer gmp manufacturing ucart19 ucart123 allogeneic universal 2015 financial results

News and Trends 16 Mar 2016

How Good was 2015 for the French Universal CAR-T Biotech?

Cellectis (France) has now released its financial results for 2015. What happened and what the prospects for 2016 and long-term? It was a really packed year for Cellectis, the French Champion for universal, off-the-shelf CAR-T treatments. The Biopharma saw significant advances in multiple fronts, from clinical development to financing. The first therapy initially developed by […]

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

mission therapeutics sachs interview zurich labiotech biotech

News and Trends 16 Mar 2016

Interviewing the Biotech which raised the Biggest European Round in 2016 so far

Yesterday I flew to Switzerland for the day, to gage what was going on at the 9th Annual Sachs conference for European Biotech CEOs. Here I had the chance to Interview Cambridge UK’s Mission Therapeutics on investment and technology.. Panel discussions covered Partnering and Investment for various therapeutic platforms – in MedTech, Diagnostics and generally ‘Israel’ (and […]

March 16, 2016 - 1 minutemin - By Philip Hemme

nanobiotix private placement €21M nanoxray sarcoma liver head neck prostate cancer nbtxr3 nanomedicine radiotherapy localized

News and Trends 15 Mar 2016

French Nanomedicine Biotech Gets €21M to Kill Cancer with ‘Beam Rays’

Nanobiotix (France) has had a successful private placement in, raising €21.3M to advance the clinical development of its localised radiotherapy for Cancer. Located in Paris’ superbiocluster, Nanobiotix wants to change the way cancer is treated – but in a different way from most Biotech strategies. It is developing NanoXRay, a paradigm-shifting nanotechnology for localised radiotherapy. Nanobiotix has […]

March 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

nature cancer reviews lumd leiden isa pharmaceuticals immuno oncology immunotherapies checkpointblocking chemotherapy immunosupression

News and Trends 11 Mar 2016

Reviewing Immuno-Oncology: What works and what doesn’t

Researchers from Leiden University Medical Center (LUMC) and ISA Pharmaceuticals (Netherlands) have authored an extensive review of what is working in immuno-oncology – and what hasn’t. The review was accepted in the well-known journal Nature Reviews Cancer and it covers the findings of 250 peer-reviewed papers about immunotherapies. Immuno-oncology is radically changing the way cancer is being […]

March 11, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 11 Mar 2016

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

From East to West, this week we say goodbye to Hungary and head up towards Queen Elizabeth II’s United Kingdom. Cambridge, known for its World renowned Academia is where Mission Therapeutics, our Biotech of the Week is located. City: Cambridge (UK) Founded: 2011 Employees: 30 Total raised: €110M (as of 02/2016) CEO: Anker Lundemose Mission: Founded in 2011, Mission Therapeutics, […]

March 11, 2016 - 1 minutemin - By Joachim Eeckhout

aprea ovarian cancer p53 protein apr 246 karolinska versant ventures 5am ventures healthcap

News and Trends 10 Mar 2016

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

Aprea (Sweden) is not a well-know Biotech (yet), but has succeeded in raising €46M from big investors in the US and Europe. Why? For its First-in-class potential for a famous cancer target… Aprea started in 2003 as a spin-off from cancer research at Karolinska Institutet, in its technology-transfer program. This Biotech has a promising candidate […]

March 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

prime priority medicines ema european medicine agency breakthrough therapy fast track biotech

News and Trends 9 Mar 2016

EMA Launches its own Fast Track for Breakthrough Therapies

The European Medicine Agency (EMA) is launching a priority scheme for therapies addressing unmet medical needs, similar to the FDA’s fast track. The key objective is to help European patients get earlier access to therapies that could be lifesaving, and this could have significant impact on the European Biotech industry. This new PRIME fast-track will include a […]

March 9, 2016 - 2 minutesmins - By Denise Neves Gameiro

karolinska development akinion acute myeloid leukemia aml liver toxicity phase II akn 028 tyrosine kinase inhibitor

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M hit in its portfolio valuation. Sad news for Akinion. This Stockholm-based drug developer decided to halt the development of its lead candidate, APN-028. This happens after […]

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

cancer top 8 biotech immunooncology europe oncology

News and Trends 7 Mar 2016

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost… Simply by having a quick look through our articles, we can easily confirm that cancer is one of the World’s main concerns in […]

March 7, 2016 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

CAR-T Startup Gets €51M from Top&New Investors

Roche signs a €900M deal with an Immunotherapy Biotech in Boston

GSK partners to Scale Manufacturing of CAR-T Therapies

How Good was 2015 for the French Universal CAR-T Biotech?

Interviewing the Biotech which raised the Biggest European Round in 2016 so far

French Nanomedicine Biotech Gets €21M to Kill Cancer with ‘Beam Rays’

Reviewing Immuno-Oncology: What works and what doesn’t

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

EMA Launches its own Fast Track for Breakthrough Therapies

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!